Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00382070 · ClinicalTrials.gov registry record · Phase 3
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Phase 3 study of Breast Cancer, sponsored by NSABP Foundation.
- Active
- Registry status
- Phase 3
- Development phase
- 3,966
- Enrollment target
- 20
- Study locations
NCT00382070 is a Phase 3 study of Breast Cancer that is active but no longer recruiting, run by NSABP Foundation. The registered enrollment target is 3,966 participants, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (42% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT00382070, a Phase 3 study of Breast Cancer, is active but no longer recruiting, sponsored by NSABP Foundation.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 3,966 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Letrozole
Study Locations (20)
California
- Alta Bates Summit Comprehensive Cancer Center - Berkeley
- Providence Saint Joseph Medical Center - Burbank - Burbank
- Peninsula Medical Center - Burlingame
- East Bay Radiation Oncology Center - Castro Valley
- Eden Medical Center - Castro Valley
- Valley Medical Oncology Consultants - Castro Valley - Castro Valley
- Cancer Care Center at John Muir Health - Concord Campus - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- North Bay Cancer Center - Fairfield
- Kaiser Permanente - Fremont - Fremont
- Valley Medical Oncology - Fremont
- Cancer Care Associates - Fresno
- Virginia K. Crosson Cancer Center at St. Jude Medical Center - Fullerton
- Glendale Memorial Hospital Comprehensive Cancer Center - Glendale
- Marin Cancer Institute at Marin General Hospital - Greenbrae
Alabama
- Regional Medical Center - Anniston
- Providence Cancer Center at Providence Hospital - Mobile
Alaska
- Providence Cancer Center - Anchorage
- Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital - Fairbanks
Arkansas
- Arkansas Cancer Research Center at University of Arkansas for Medical Sciences - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,966 participants |
| Start Date | 2006-08 |
| Est. Completion | 2025-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00382070
The ClinicalTrials.gov registry entry for NCT00382070 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 3,966 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 2,800-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (42% higher). The listed sponsor is NSABP Foundation, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00382070 reports 20 study locations spanning 4 distinct geographic areas - top geographies include California, Alabama, Alaska.
Frequently Asked Questions
What is clinical trial NCT00382070 about?
NCT00382070 is a clinical study titled "Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer". RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breas...
What is the current status of trial NCT00382070?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 3,966 participants. The study started on 2006-08. Estimated completion is 2025-04.
What conditions does trial NCT00382070 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00382070?
The interventions under investigation include: Placebo (OTHER), Letrozole (DRUG).
Who is sponsoring clinical trial NCT00382070?
This trial is sponsored by NSABP Foundation, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00382070 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.